Bruton's tyrosine kinase inhibition for the treatment of allergic disorders.

Ann Allergy Asthma Immunol · 2024 · PMC11222055 · PMID 38492772

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Though autoantibody titer data have not been released from remibrutinib trials, data from trials with the highly-selective, noncovalent BTKi fenebrutinib (Genentech) indicate a clear trend.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.